國家衛生研究院 NHRI:Item 3990099045/4603
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12340/13424 (92%)
造访人次 : 2036728      在线人数 : 478
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4603


    题名: Control of virus-\associated hemophagocytic syndrome by peroxisome proliferator activated receptor agonists in a rabbit model
    作者: Hsieh, WC;Lan, BS;Su, IJ
    贡献者: Division of Clinical Research
    摘要: Hemophagocytic syndrome (HPS) is a fatal complication of severe viral infections such as Epstein-Barr virus (EBV) and recently, SARS CoV and H5N1 influenza. The pathogenesis of HPS is presumed to result from an enhanced Th1 cytokine secretion and systemic macrophage activation. Since peroxisome proliferators activated receptor (PPAR) agonists, regulators of cholesterol metabolism, have been shown to exhibit profound effects on the inhibition of proinflammatory cytokines and macrophage activation, rosiglitazone, a PPAR-gamma agonist, was adopted for the potential control of HPS using a rabbit model of Herpesvirus papio (HVP, an EBV homologue)-associated HPS. In vitro, rosiglitazone was shown to inhibit macrophage activation and secretion of tumor necrosis factor-alpha through inhibition of NFkB signaling in U937 cell line. Different doses of rosiglitazone were fed to rabbits after intravenous injection of 5 × 107 copies of HVP virus at different time courses (7 days and 20 days, respectively) of infection. As compared to the control group which succumbed consistently at around one month, the 4 mg rosiglitazone-treated group showed significant improvement of survival when fed at early stage (7 days) of infection (p < 0.01), while a higher dosage (8 mg) is needed to achieve therapeutic effect at advanced stage (20 days) of infection (p < 0.05). The viral load, TNF-alpha cytokine levels, and laboratory parameters also showed significant improvement in the rosiglitazone-treated group. Therefore, rosiglitazone, in addition to its therapeutic effect for metabolic syndrome, appears to represent a potential regimen for the control of HPS associated with virus infections.
    日期: 2008-12
    關聯: International Journal of Infectious Diseases. 2008 Dec;12:E168-E169.
    Link to: http://dx.doi.org/10.1016/j.ijid.2008.05.420
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1201-9712&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000263287800419
    显示于类别:[蘇益仁(2002-2015)] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000263287800419.pdf56KbAdobe PDF497检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈